Claims for Patent: 6,335,369

Summary for Patent: 6,335,369

Title:	Treating chronic uremic patients undergoing periodical dialysis
Abstract:	Chronic uremic patients undergoing periodical dialysis are treated with carnitine or one of its salts to prevent or treat carnitine deficiency in patients with end stage renal disease. An effective dose of carnitine, preferably L-carnitine fumarate, is administered preferably intravenously into the venous return line after each dialysis session.
Inventor(s):	Cavazza; Claudio (Rome, IT)
Assignee:	Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (Rome, IT)
Application Number:	09/761,639
Patent Claims:	1. A method of preventing or treating carnitine deficiency in chronic uremic patients undergoing periodic dialysis comprising administering to the patient at the conclusion of dialysis an effective amount of L-carnitine or a pharmaceutically acceptable salt thereof. 2. The method of claim 1, wherein administration is by the intravenous route. 3. The method of claim 1, wherein administration is by the peritoneal route. 4. The method of claim 1, wherein from about 10 to about 20 mg/kg body weight of carnitine, calculated as L-carnitine, is administered into a venous return line at the end of a dialysis session. 5. The method of claim 1, wherein L-carnitine fumarate is administered. 6. A method of preventing or treating carnitine deficiency in chronic uremic patients undergoing periodic dialysis comprising administering to the patient at the conclusion of dialysis an effective amount of L-carnitine fumarate. 7. The method of claim 6, wherein administration is by the intravenous route. 8. The method of claim 6, wherein administration is by the peritoneal route. 9. The method of claim 6, wherein from about 10 to about 20 mg/kg body weight of carnitine, calculated as L-carnitine, is administered into a venous return line at the end of a dialysis session. 10. A method of preventing carnitine deficiency in end stage uremic patients undergoing periodic dialysis over an extended period of time, said method comprising administering to the patent at the conclusion of each dialysis session an effective amount of L-carnitine or a pharmaceutically acceptable salt thereof. 11. The method of claim 10, wherein administration is by the intravenous route. 12. The method of claim 10, wherein administration is by the peritoneal route. 13. The method of claim 10, wherein from about 10 to about 20 mg/kg body weight of carnitine, calculated as L-carnitine, is administered into a venous return line at the end of a dialysis session. 14. The method of claim 10, wherein L-carnitine fumarate is administered.